VJVirtual | The future of chemo-free approaches in adults with Ph+ ALL
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, considers chemotherapy-free strategies for adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), and discusses next steps following the recently published results of the Phase II study evaluating induction dasatinib followed by consolidation blinatumomab in adult, Ph+ ALL. Prof. Foà details a future clinical study comparing the third-generation tyrosine kinase inhibitor, ponatinib, in combination with blinatumomab against a chemotherapy-based regimen, in order to improve the molecular response rate of Ph+ ALL patients and discern whether chemotherapy-free approaches are superior within this patient population. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
